Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
В России зарегистрирован препарат глофитамаб – первое биспецифическое антитело к CD20xCD3 для лечения пациентов с диффузной В-клеточной крупноклеточной лимфомой
В России зарегистрирован препарат глофитамаб – первое биспецифическое антитело к CD20xCD3 для лечения пациентов с диффузной В-клеточной крупноклеточной лимфомой
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Могут ли биспецифические антитела изменить парадигму и цели терапии пациентов с рецидивами неходжкинских лимфом? Интервью с И.В. Поддубной. Современная Онкология. 2023;25(4):417-20 [Can bispecific antibodies change the paradigm and goals of therapy for patients with relapsed non-Hodgkin lymphomas? Interview with Poddubnaya IV. Journal of Modern Oncology. 2023;25(4):417-20 (in Russian)]. DOI:10.26442/18151434.2023.4.202515
2. Bacac M, Klein C, Umana P. CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016;5(8):e1203498. DOI:10.1080/2162402X.2016.1203498
3. Bacac M, Colombetti S, Herter S, et al. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. Clin Cancer Res.
2018;24(19):4785-97. DOI:10.1158/1078-0432.CCR-18-0455
4. Ferl GZ, Reyes A, Sun LL, et al. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clin Transl Sci. 2018;11(3):296-304. DOI:10.1111/cts.12535
5. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;387(24):2220-31. DOI:10.1056/NEJMoa2206913
6. Hutchings M, Carlo-Stella C, Morschhauser F, et al. P433: Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume. ASH2023 abstracts. Available at: https://ash.confex.com/ash/2023/webprogram/Paper173951.html. Accessed: 23.09.2024.
7. Bock AM, Nowakowski GS, Wang Y. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Curr Treat Options Oncol. 2022;23(2):155-70. DOI:10.1007/s11864-021-00925-1
2. Bacac M, Klein C, Umana P. CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016;5(8):e1203498. DOI:10.1080/2162402X.2016.1203498
3. Bacac M, Colombetti S, Herter S, et al. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. Clin Cancer Res.
2018;24(19):4785-97. DOI:10.1158/1078-0432.CCR-18-0455
4. Ferl GZ, Reyes A, Sun LL, et al. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clin Transl Sci. 2018;11(3):296-304. DOI:10.1111/cts.12535
5. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;387(24):2220-31. DOI:10.1056/NEJMoa2206913
6. Hutchings M, Carlo-Stella C, Morschhauser F, et al. P433: Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume. ASH2023 abstracts. Available at: https://ash.confex.com/ash/2023/webprogram/Paper173951.html. Accessed: 23.09.2024.
7. Bock AM, Nowakowski GS, Wang Y. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Curr Treat Options Oncol. 2022;23(2):155-70. DOI:10.1007/s11864-021-00925-1
2. Bacac M, Klein C, Umana P. CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016;5(8):e1203498. DOI:10.1080/2162402X.2016.1203498
3. Bacac M, Colombetti S, Herter S, et al. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. Clin Cancer Res.
2018;24(19):4785-97. DOI:10.1158/1078-0432.CCR-18-0455
4. Ferl GZ, Reyes A, Sun LL, et al. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clin Transl Sci. 2018;11(3):296-304. DOI:10.1111/cts.12535
5. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;387(24):2220-31. DOI:10.1056/NEJMoa2206913
6. Hutchings M, Carlo-Stella C, Morschhauser F, et al. P433: Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume. ASH2023 abstracts. Available at: https://ash.confex.com/ash/2023/webprogram/Paper173951.html. Accessed: 23.09.2024.
7. Bock AM, Nowakowski GS, Wang Y. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Curr Treat Options Oncol. 2022;23(2):155-70. DOI:10.1007/s11864-021-00925-1
________________________________________________
2. Bacac M, Klein C, Umana P. CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016;5(8):e1203498. DOI:10.1080/2162402X.2016.1203498
3. Bacac M, Colombetti S, Herter S, et al. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. Clin Cancer Res.
2018;24(19):4785-97. DOI:10.1158/1078-0432.CCR-18-0455
4. Ferl GZ, Reyes A, Sun LL, et al. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clin Transl Sci. 2018;11(3):296-304. DOI:10.1111/cts.12535
5. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;387(24):2220-31. DOI:10.1056/NEJMoa2206913
6. Hutchings M, Carlo-Stella C, Morschhauser F, et al. P433: Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume. ASH2023 abstracts. Available at: https://ash.confex.com/ash/2023/webprogram/Paper173951.html. Accessed: 23.09.2024.
7. Bock AM, Nowakowski GS, Wang Y. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Curr Treat Options Oncol. 2022;23(2):155-70. DOI:10.1007/s11864-021-00925-1
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.